Transcoronary Platelet Thromboxane A₂ Formation without Platelet Trapping in Patients with Coronary Stenosis - Effect of Sulphinpyrazone Treatment

Summary

Platelet count, and plasma thromboxane B₂ (TXB₂) and circulating platelet aggregates (CPA) were determined in the coronary sinus (CS), aortic bulb (AO) and cubital vein (V) in 21 patients with stable angina and in 6 control subjects before and after atrial pacing (AP). TXB₂ measurements were repeated before and after AP in 6 of the 21 angina patients after 15 days’ sulphinpyrazone treatment. Platelet count and CPA ratio were similar in angina patients and controls at all three sampling sites and were unchanged at AP peak. In the controls, basal TXB₂ values in CS, AO and V were not significantly different and were unchanged at AP peak. In the angina patients compared with the controls, basal TXB₂ values in the AO, CS and V were not significantly different whereas the CS/AO TBX₂ ratio was significantly higher; at AP-induced ischaemia, CS TXB₂ was significantly increased and the CS/AO TXB₂ ratio was increased. A weak but significant direct correlation was found between CS/ AO TXB₂ ratio and coronary score. Sulphinpyrazone treatment reduced CSTXB₂ levels at rest and after AP, but not the ischaemic threshold at AP.

Keywords

Thromboxane A₂ - Transcoronary platelet activity - Stable angina - Sulphinpyrazone

• References

• 1 Anturane Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 1980; 302: 250-256
• 2 Anturan Reinfarction Italian Study Group. Sulphinpyrazone in post-myocardial infarction. Lancet 1982; 1: 237-242
• 3 Wu KK, Hoak JC. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974; 2: 924-927
• 4 Granström E, Kindahl H, Samuelsson B. Radioimmunoassay for thromboxane B₂ . Anal Lett 1976; 9: 611-627
• 5 Leese HJ, Brouk JR. Automated fluorometric analysis of micromolar quantities of ATP, glucose and lactic acid. Anal Biochem 1972; 45: 211-221
• 6 Leaman DM, Brower RW, Meester GT, Serruys P, Van den Brandt M. Coronary artery atherosclerosis: severity of the disease, severity of angina pectoris and compromised left ventricular function. Circulation 1981; 63: 285-292
• 7 Lewy RI, Wiener L, Walinsky P, Lefer AM, Silver MJ, Smith JB. Thromboxane release during pacing-induced angina pectoris: possible vasocon-strictor influence on the coronary vasculature. Circulation 1980; 61: 1165-1171
• 8 Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson TJ. Release of prostaglandins and thromboxane into the coronary circulation of patients with ischemic heart disease. N Engl J Med 1981; 304: 685-691
• 9 Mehta P, Mehta J, Pepine CJ, Miale TD, Burger CPlatelet. Normal versus diseased coronary arteries. Thromb Res 1979; 14: 423-432
• 10 Thaulow E, Dale J, Kjekshus J, Simonsen S, Hovig T, Solum N-O. Pacing induced angina and platelet reactivity. Scand J Clin Lab Invest 1982; 42: 607-611
• 11 Verheugt FW, Serruys PW, van VlietH, Spijkers A, Hugenholtz PG. Intracoronary platelet release in patients with and without coronary artery disease. Thromb Haemostas 1983; 49: 28-31
• 12 Mehta J, Mehta P, Pepine CJ. Platelet aggregation in aortic and coronary sinus blood in patients with and without coronary disease. Circulation 1978; 58: 881-886
• 13 Dalai JJ, Sheridan DJ, Bloom AL, Henderson AH. Platelet aggregates and coronary spasm. Lancet 1980; 2: 1146-1147
• 14 Kaplan KL, Owen J. Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202
• 15 Kinlough-Rathbone RL, Packham MA, Reimers HJ, Cazenave JP, Mustard JF. Mechanisms of platelet shape change, aggregation and release induced by collagen, thrombin or A23.187. J Lab Clin Med 1977; 90: 707-719
• 16 Cowan DH. Platelet adherence to collagen: role of prostaglandin-thromboxane synthesis. Br J Haematol 1981; 49: 425-434
• 17 Levy-Toledano S, Maclouf J, Bryon P, Savariau E, Hardisty RM, Caen JP. Human platelet activation in the absence of aggregation: a calcium-dependent phenomenon independent of thromboxane formation. Blood 1982; 59: 1078-1085
• 18 Robertson RM, Robertson D, Roberts LJ, Maas RL, Fitzgerland GA, Friesinger GC, Oates JA. Thromboxane A₂in vasotonic angina pectoris Evidence from direct measurements and inhibitor trials. N Engl J Med 1981; 304: 998-1003
• 19 Chierchia S, De Caterina R, Crea F, Patrono C, Maseri A. Failure of thromboxane A₂blockade to prevent attacks of vasospastic angina. Circulation 1982; 66: 702-705